A new Elmiron medical study about cases of macular toxicity related to PPS exposure suggests that established maculopathy patients should be questioned regarding any Elmiron use in the past. This will help eye doctors determine whether this person may have Elmiron maculopathy secondary to pentosan polysulfate (PPS) toxicity.
The findings of this new study about Elmiron maculopathy are presented in this article, “New Insights Into Pentosan Polysulfate Maculopathy”, posted on January 21, 2021, by the medical journal Ophthalmic Surgery, Lasers and Imaging Retina, or OSLI Retina.
From that January 2021 medical journal article about Elmiron maculopathy we get this background information set forth in its Introduction section:
Macular toxicity secondary to pentosan polysulfate sodium (PPS) (Elmiron; Janssen Pharmaceuticals, Beerse, Belgium) was first reported in 2018. PPS is the only U.S. Food and Drug Administration (FDA)-approved oral treatment for interstitial cystitis (IC), a painful urological condition affecting approximately 45 in 100,000 women and eight in 100,000 men globally.
A significant contribution of this new Elmiron medical study to the medical literature has to do with how one might diagnose Elmiron maculopathy secondary to pentosan polysulfate (PPS) toxicity. From the Conclusions section of the January 2021 OSLI Retina article:
Patients with long-term [use of Elmiron, i.e., exposure to PPS] may present with various pre-existing diagnoses but most PPS toxicity cases manifest with a specific constellation of OCT, FAF, and [OCT angiography (OCTA)] findings. Established maculopathy patients should be questioned regarding exposure to PPS, especially with negative genetic testing or atypical presentations.
Our law firm is investigating possible Elmiron lawsuits for patients who have suffered vision loss due to Elmiron maculopathy. If we can be of assistance to you or someone else regarding an Elmiron vision loss case, you can submit an Elmiron Case Evaluaton Form online or you can call us on our toll-free number: 800-426-9535.[Read article in full at original source]